Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo by Tim Boyle/Getty Images

Toys "R" Us formally launched its liquidation process shortly after midnight, via a bankruptcy court filing. This came hours after more than 33,000 U.S. employees were told their jobs are likely to disappear.

Bottom line: There is plenty of blame to go around, including for the private equity firms that bought Toys "R" Us in 2005, the senior lenders who control it now and an increased focus on toys by generalist retailers like Amazon and Wal-Mart.

Nothing is finalized yet. There is still some hope that around 200 strong-performing U.S. stores could be merged with the much-healthier Canadian operation.

A key number is $81 million, which was EBITDA for U.S. stores in Q4 2017 (i.e., holiday season). That's well below $374 million in Q4 15 and $347 million in Q4 16, not to mention below lender projections of around $330 million.

Finger pointing
  • Private equity firms Bain Capital and KKR paid too much, larded on too much debt, paid themselves handsomely and didn't adequately foresee the changing face of American retail.
  • The senior lenders seem to have decided that it would be more lucrative to burn the whole thing down, rather than salvage hundreds of viable stores and thousands of jobs.
  • Amazon, Wal-Mart and Target threaten most specialty retailers, but took particular aim at the toy market. Toys "R" Us simply couldn't compete, and wasn't helped by an early 2000's belief that it would be better to partner with Amazon than fight against it.

Toys "R" Us CEO Dave Brandon told me two years ago that a key to specialty retail success would be exclusive product. Either Toys "R" Us and Babies "R" Us didn't have enough of it, or he was wrong. But Brandon got well compensated either way.

Go deeper

Ina Fried, author of Login
6 mins ago - Technology

Apple sets September quarter sales record despite later iPhone launch

Apple CEO Tim Cook, speaking at the Apple 12 launch event in October. Photo: Apple

Apple on Thursday reported quarterly sales and earnings that narrowly exceeded analysts estimates as the iPhone maker continued to see strong demand amid the COVID-19 pandemic.

What they's saying: The company said response to new products, including the iPhone 12 has been "tremendously positive" but did not give a specific forecast for the current quarter.

Supreme Court rejects second GOP effort to cut absentee ballot deadline in N.C.

Photo: Robert Alexander/Getty Images

The Supreme Court, for the second time in two days, rejected a GOP request to shorten the deadline mail-in ballots must be received by North Carolina officials to be counted.

The state of play: The state's deadline had been extended from 3 days to 9 days post-Election Day.

2 hours ago - Podcasts

The vaccine race turns toward nationalism

The coronavirus pandemic is worsening, both in the U.S. and abroad, with cases, hospitalizations and deaths all rising.

Axios Re:Cap digs into the state of global vaccine development — including why the U.S. and China seem to going at it alone — with medicinal chemist and biotech blogger Derek Lowe.